Anti-Phosphatidyl Serine IgG/IgM ELISA Kit

Produktnummer ABIN930721

Produktdetails

Target: Anti-Phosphatidyl Serine IgG/IgM

Reaktivität: Chemical

Nachweismethode: Colorimetric

Methodentyp: Sandwich ELISA

Applikation: ELISA

Analytische Methode: Quantitative

Produktmerkmale: ELISA kit for the detection of Phosphatidyl Serine IgG/IgM in the research laboratory
Alternative Names: Phosphatidyl Serine IgG/IgM ELISA kit

Anwendungsinformationen

Applikationshinweise: Optimal conditions to be determined by end-user

Plattentyp: Pre-coated

Testdurchführung:

AntiPhosphatidyl Serine is an indirect solid phase enzyme immunometric assays (ELISA). It is designed for the quantitative measurement of IgG or IgM class autoantibodies directed against negativelycharged phospholipids. The microplate is coated with highly purified Phosphatidyl Serine. AntiPhospholipid autoantibodies require beta2Glycoprotein I as a cofactor for binding. The microplate is therefore saturated with human beta2Glycoprotein I. The microplates can be divided into 12 modules of 8 wells each or can be used completely for 96 determinations. Each well can be separated from the module (

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Lagerung: 4 °C

Informationen zur Lagerung: Store at 2-8 °C.

Antigendetails

Target: Anti-Phosphatidyl Serine IgG/IgM

Sub Type: Fusionprotein

Substanzklasse: Antibody

Hintergrund: The first study of anti-phospholipid antibodies began in 1906, when Wasserman introduced a serological test for Syphilis. In 1942, the active component was found to be a phospholipid, which was designated Cardiolipin. In the 1950s it became clear that a number of people had positive tests for syphilis without any evidence of the disease. This phenomenon was referred to as the biological false positive serological test for syphilis. A high prevalence of autoimmune disorders, including systemic lupus erythematosus (SLE) and Sj grens Syndrome occurred in this group of patients. The presence of circulating anticoagulants in patients with SLE was first documented in 1952 and was associated with increased risk of paradoxical Thrombosis in 1963. The term Lupus Anticoagulant (LA) was first used in 1972, is clearly a misnomer, because LA is more frequently encountered in patients without lupus and is associated with thrombosis rather than abnormal bleeding. During the last years it became clear that the optimal binding of anti phospholipid antibodies is dependent on a cofactor termed beta-2-glycoprotein I (apolipoprotein H) (GPI). GPI is a 50 kDa beta-2-globulin occurring in plasma at a level of 200 g/mL. It has been found that beta-2-glycoprotein I (beta2GPI) inhibits the intrinsic coagulation pathway and, therefore, it is involved in the regulation of blood coagulation. beta2GPI is associated in vivo with negativelycharged substances, e.g. anionic phospholipids, heparin and lipoproteins. The phospholipid binding region is located on its fifth domain. Under the acronym aPL (antiPhospholipid antibodies) antibodies against negatively charged phospholipids, such as CL (Cardiolipin), LA (Lupus Anticoagulant), PS (Phosphatidylserine), PI (Phosphatidylinositol) and PA are summarised. Of these, CL is the phospholipid most commonly used as antigen to test for aPL by ELISA. Some antisera which bind cardiolipin coated ELISA plates can also bind plates coated with other negatively charged phospholipids, such as phosphatidylserine (PS) and phosphatidic acid (PA). Some investigators have suggested that the use of PS in place of cardiolipin in ELISA tests enables more specific diagnosis. These antigens are less commonly used and their additional use can improve the clinical sensitivity in patient samples with suspected APS (Anti-phospholipid Syndrome), but at this time it seems that they can't replace the measurement of autoantibodies against Cardiolipin.
Synonyms: Phosphatidyl Serine IgG/IgM ELISA kit.